Our purpose is to accelerate the development of cancer medicines and treatments
Rewriting Cancer
We are delighted to announce our involvement in Rewriting Cancer, a series produced for UICC by BBC StoryWorks Commercial Productions. This unique project examines the complexity of cancer and the changes in treatments that are required to achieve better outcomes for patients. Watch and learn how we and the other participants are Rewriting Cancer. In oncology we all share a common goal to improve the lives of patients.
Talk to our team
We’d like to hear from you
Read the latest news from Ellipses Pharma
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent With Potential as a Next Generation Checkpoint Inhibitor London, February 11, 2025: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it is to develop a next-generation immuno-oncology drug which could [...]
Ellipses Launches Clinical Trial Programme in Middle East
Ellipses Pharma Launches Pioneering Clinical Trial Programme in Middle East London, December 23, 2024: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it has inaugurated the first large-scale Phase 1/2 oncology clinical study of its kind in the [...]
Ellipses Pharma publishes the latest data from an ongoing Phase 1/2 clinical trial of EP0042
Ellipses Pharma publishes the latest data from an ongoing Phase 1/2 clinical trial of EP0042 at ASH 2024 London, UK, 9th December 2024: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, has published the latest data from an ongoing Phase 1/2 clinical trial of EP0042, [...]
